Drug Trial Radar · NCT01212471
A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease
Last checked: Nov 20, 2026Latest source record: Sep 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
840
Actual
Start
Sep 2010
Primary completion
Aug 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Sep 30, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A dose ranging study to evaluate safety and efficacy of bromfenac ophthalmic solution in dry eye disease.
Conditions
- Dry Eye Syndrome
Interventions
Bromfenac Ophthalmic Solution ADrug
sterile ophthalmic solution
Bromfenac Ophthalmic Solution BDrug
sterile ophthalmic solution
Placebo ComparatorDrug
sterile ophthalmic solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Ocular Surface Disease Index (OSDI) Total ScoreTime frame: 42 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ISTA Pharmaceuticals, Inc.
Irvine, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.